Editorial Calendar

Date
Topic
Type
Jan 3
New drug approvals — All new drugs approved in 2021, with analysis
Special report

An in-depth list of every new drug approval from the previous year, recognition of the companies that brought them to market, and an analysis of their impact on the market at large.

Previous: 20222021
Jan 10-12
Endpoints at #JPM22
Event

The biopharma world kicks off each year with a frenzy of activity at JP Morgan. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D.

Previous: 20222021
Jan 25
The checkpoint debate is about to get real
In Focus Special Report

Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.

Authors: Zachary Brennan & Jason Mast
Jan 27
The checkpoint debate is about to get real
In Focus Editorial Webinar

Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.

Moderator: Kyle Blankenship
Jan TBD
Endpoints Pharma Email Report launch
Feb 7
The top 100 biotech VCs
Editorial Feature

Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will also host a webinar looking at a fascinating piece of the funding scene in the industry.

Author: John Carroll
Previous: Top VCs 2021
Feb 7
The top 100 biotech VCs
Editorial Webinar

Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will host a webinar looking at a fascinating piece of the funding scene in the industry.

Author: John Carroll
Feb TBD
Top blockbuster drugs
Editorial Feature

A list of drugs in development with the biggest launch potential

Previous: 2021
Feb TBD
Top 10 setbacks and snafus, H2 2021
Special report

A list of 10 high-profile mistakes in the industry, examined and analyzed

Previous: H1 2021 report
Feb 22
AI faces its moment of truth
In Focus Special Report

Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.

Topic: AI/ML
Author: Max Gelman
Feb 24
AI faces its moment of truth
In Focus Editorial webinar

Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.

Topic: AI/ML
Moderator: Kyle Blankenship
Mar 22
Endpoints 100
Editorial Feature

Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more

Previous: 2021
Mar 29
The new psychedelic age in biotech
In Focus Special report

Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.

Topic: Psychedelics research/depression
Author: Nicole DeFeudis
Mar 31
The new psychedelic age in biotech
In Focus Editorial webinar

Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.

Topic: Psychedelics research/depression
Moderator: Nicole DeFeudis
Apr 2-4
Editorial coverage of ACC
Conference coverage
Apr 5
20 under 40
Editorial Feature

Profiles of young standouts in the biopharma field — the key factors in their success, and their goals as the next generation of industry leaders.

Previous: 20212020
Apr 8-13
Editorial coverage of AACR
Conference coverage
Apr 11
AACR special issue
Apr 26
Most influential pharma marketing execs
Editorial Feature
Apr 26
The top 15 R&D ops: Who’s got clout?
In Focus Special report

Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.

Topic: R&D trends
Author: John Carroll
Previous: 2019
Apr 28
The top 15 R&D ops: Who’s got clout?
In Focus editorial webinar

Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.

Topic: R&D trends
Moderator: John Carroll
May 24
New biomarkers are remapping the world of cancer studies
In Focus Special report

In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?

Topic: Clinical trials/regulators
Author: John Carroll
May 26
New biomarkers are remapping the world of cancer studies
In Focus Editorial Webinar

In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?

Topic: Clinical trials/regulators
Moderator: John Carroll
Jun 3-7
Editorial coverage of ASCO
Conference coverage
Jun 6
ASCO special issue
Jun 6
Endpoints at #ASCO22
Event

Every year the biopharma industry turns to ASCO to help define where cancer drug R&D is headed. Endpoints News will bring together a group of experts to discuss the most important presentations at the conference, with insights on the winners and losers at ASCO22.

Previous: 202220212020
Jun 13-16
Endpoints at #BIO22
Event

A series of presentations with our take on the most important biopharma R&D trends for the global audience convened during BIO.

Jun 19-23
Editorial coverage of DIA
Conference coverage
Jun 21
Endpoints at #DIA22
Event

A fireside chat and subsequent panel discussion with top analysts and drug makers to unpack the shifting regulatory landscape and other key issues across the life sciences industry.

Previous: 20222021
Jun 20-24
Editorial coverage of Cannes Lions
Conference coverage
Jun 20-24
Cannes Lions special issue
Jun 28
Mission critical: Cybersecurity
In Focus Special report

Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.

Topic: Cybersecurity
Author: Amber Tong
Jun 30
Mission critical: Cybersecurity
In Focus Editorial Webinar

Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.

Topic: Cybersecurity
Moderator: John Carroll
Jul 6
Top 10 setbacks and snafus, H1 2022
Editorial Feature

A list of 10 high-profile mistakes in the industry, examined and analyzed

Previous: H1 2021 report
Jul 26
Pain R&D: Plenty of pain to go around, but who’s making gains?
In Focus Special Report

Plenty of pain to go around, but who’s making gains? The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints News will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.

July 28
Pain R&D: Plenty of pain to go around, but who’s making gains?
In Focus Editorial Webinar

Plenty of pain to go around, but who’s making gains? The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints news will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.

Aug 9
Most influential execs in biopharma
Editorial Feature
Previous: 2021
Aug 26-29
Editorial coverage of ESC
Conference coverage
Aug 30
Parkinson’s R&D: Have we finally reached a turning point?
In Focus Special Report

Have we finally reached a turning point? The headlines haven’t been encouraging when it comes to Parkinson’s, one of the toughest targets in R&D. AbbVie broke off a deal on alpha-synuclein as a target. One of the gene therapy efforts has foundered. There are a slate of GLP-1 and gene therapy programs in the clinic, but what realistically are their chances? Anyone who can make a significant advance, though, stands to gain access to one of the largest markets in medicine. What are the leading scientists saying about the road ahead?

Sept 1
Parkinson’s R&D: Have we finally reached a turning point?
In Focus Editorial Webinar

Have we finally reached a turning point? The headlines haven’t been encouraging when it comes to Parkinson’s, one of the toughest targets in R&D. AbbVie broke off a deal on alpha-synuclein as a target. One of the gene therapy efforts has foundered. There are a slate of GLP-1 and gene therapy programs in the clinic, but what realistically are their chances? Anyone who can make a significant advance, though, stands to gain access to one of the largest markets in medicine. What are the leading scientists saying about the road ahead?

Sept 9-13
Editorial coverage of ESMO
Conference coverage
Sept 12
ESMO special issue

The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.

Previous: 2021
Sept 12
Endpoints at #ESMO22
Event

The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.

Previous: 2021
Sept 21
Endpoints 100
Editorial Feature

Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more

Previous: 2021
Sept 22
Endpoints 11: Our picks of the most promising private biotechs of the year
Editorial Feature

In-depth profiles of the top 11 biotech startups, as selected by Endpoints, and an analysis of the trends that support their promise

Previous: 20212020
Sept 22
Endpoints 11
Event

John Carroll will be awarding the coveted Endpoints 11 — to the CEOs and R&D leaders at each of these companies during our event that celebrates innovative science and entrepreneurship

Previous: 20212020
Sept 27
The clinical trial recruitment crisis hits home
In Focus Special Report

A host of issues have clouded patient recruitment for clinical trials, causing some severe issues for drug developers. Patient access to drug studies -- particularly in oncology -- has been a growing problem, along with key challenges in hiring site staff and the limitations involved with the structures now in place for managing trials. Endpoints News’ Kyle LaHucik has been digging deep into this, and offers a detailed look at the problems and potential solutions

Author: Kyle LaHucik
Sept 29
The clinical trial recruitment crisis hits home
In Focus Editorial Webinar

A host of issues have clouded patient recruitment for clinical trials, causing some severe issues for drug developers. Patient access to drug studies -- particularly in oncology -- has been a growing problem, along with key challenges in hiring site staff and the limitations involved with the structures now in place for managing trials. Endpoints News’ Kyle LaHucik has been digging deep into this, and offers a detailed look at the problems and potential solutions

Moderator: Kyle LaHucik
Oct 12
The European Biopharma Summit
Event

Endpoints News will feature a prominent group of the top executives leading a new generation of European biotechs in an industry that has undergone major changes in recent years

Previous: 2021
Oct 31
The vaccine R&D revolution goes global
Editorial Feature

The pandemic changed everything in vaccine development, and now the whole world is catching up. Endpoints News senior editor Amber Tong will cover the new world of vaccine research as officials look to vaccinate against viral threats like monkeypox and the Covid variants on timelines that would have been considered impossible just 2 years ago. Tong will also cover the deep changes that are transforming vaccine manufacturing and delivery as governments prime the vaccine R&D pump with billions to support a revolution in fast development. Millions of lives are on the line as viruses now spread faster than ever.

Nov 2
The vaccine R&D revolution goes global
Editorial Webinar

The pandemic changed everything in vaccine development, and now the whole world is catching up. Endpoints News senior editor Amber Tong will cover the new world of vaccine research as officials look to vaccinate against viral threats like monkeypox and the Covid variants on timelines that would have been considered impossible just 2 years ago. Tong will also cover the deep changes that are transforming vaccine manufacturing and delivery as governments prime the vaccine R&D pump with billions to support a revolution in fast development. Millions of lives are on the line as viruses now spread faster than ever.

Nov 1-3
Editorial coverage of CPhI
Conference coverage
Nov 3
CPhI special issue
Nov 5-7
AHA Scientific Sessions
Conference coverage
Nov 7
All coverage from AHA Scientific Sessions
Nov 25
Most popular stories of 2022
Nov 29
Digital therapeutics: Software is now entering mainstream therapeutic care
In Focus Special Report

The news that a prominent insurer had decided to cover a digital therapeutic for opioid disorder spurred national headlines recently. In this case, the therapeutic had a breakthrough designation from the FDA. That payer decision underscored the potential as well as the challenges that have arisen around developing and marketing digital therapeutics, which have become a fast-growing segment within digital healthcare. DTx delivers clinical interventions directly to patients via software to treat, manage or prevent disease — ranging from behavioral health conditions to diabetes. We’ll take a close look at this burgeoning field and see where we’re headed in the years to come.

Dec 1
Digital therapeutics: Software is now entering mainstream therapeutic care
In Focus Editorial Webinar

The news that a prominent insurer had decided to cover a digital therapeutic for opioid disorder spurred national headlines recently. In this case, the therapeutic had a breakthrough designation from the FDA. That payer decision underscored the potential as well as the challenges that have arisen around developing and marketing digital therapeutics, which have become a fast-growing segment within digital healthcare. DTx delivers clinical interventions directly to patients via software to treat, manage or prevent disease — ranging from behavioral health conditions to diabetes. We’ll take a close look at this burgeoning field and see where we’re headed in the years to come.

Dec 7
Women in Biopharma
Editorial Feature

Endpoints News continues its celebration of women who are blazing trails in drug research and leaving lasting marks for others to follow. Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.

Past reports: 20212020
Dec 7
Women in Biopharma
Event

Endpoints News continues its celebration of women who are blazing trails in drug research and leaving lasting marks for others to follow. Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.

Previous: 2021 2020
Dec 10-13
Editorial coverage of ASH
Conference coverage
Dec 12
ASH special issue
Dec 12
Endpoints at #ASH22
Event

Endpoints News reports on all the top news out of the world’s premier cell and gene therapy science conference. We will convene an online panel discussion on what topics grabbed the attention of the experts.

Previous: 2021